Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
复制标题
DOI：
10.1186/s12885-018-4888-2
复制
发表时间：
2018-10-16
期刊：
影响因子：
3.8
通讯作者：
Miyoshi Y
中科院分区：
文献类型：
--
作者：
Araki K;Ito Y;Fukada I;Kobayashi K;Miyagawa Y;Imamura M;Kira A;Takatsuka Y;Egawa C;Suwa H;Ohno S;Miyoshi Y
尽管外周血参数 (PBBP) 被报道为乳腺癌患者的预后指标，但其在人表皮生长因子受体 2 (HER2) 阳性晚期乳腺癌 (ABC) 中的效用尚未得到研究。肿瘤浸润淋巴细胞 (TIL) 可能是接受帕妥珠单抗和曲妥珠单抗 (PT) 加多西他赛治疗的 HER2 阳性 ABC 患者的预测因素。我们的目的是评估 PBBP 在帕妥珠单抗和曲妥珠单抗 (PT) 联合艾日布林 (ERI) 或白蛋白结合型紫杉醇 (Nab-PTX) 治疗的 HER2 阳性 ABC 中是否具有预测价值。这项回顾性前瞻性研究纳入了两项单臂 II 期试验中 51 名患者的数据； ERI + PT（N = 30）和Nab-PTX + PT（N = 21）组合分别在临床试验号UMIN000012375和UMIN000006838下注册。我们使用前瞻性收集的数据评估 PBBP，并研究其与无进展生存期 (PFS) 的关联；我们评估了绝对淋巴细胞计数（ALC）、中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）。 ALC、NLR 和 PLR 的截止值分别设置为 1000 或 1500 个细胞/μL、2 和 250。与 ALC 1000–、<1500/μL 或 ALC < 1000/μL 的患者相比，ALC ≥1500/μL 的患者 PFS 显着改善（P = 0.0106）。高基线 ALC 与 PFS 改善显着相关（≥1500/μL；风险比 [HR]：0.3715；95% 置信区间 [CI]：0.1735–0.7955；P = 0.0108）。相比之下，PFS 的改善与 NLR 或 PLR 没有显着相关性。无论内脏转移或化疗方案如何，ALC ≥1500/μL 患者的 PFS 均得到改善。我们的结果表明，无论联合化疗方案如何，基线 ALC 都是接受 PT 治疗的 HER2 阳性 ABC 患者 PFS 的预测因素。抗肿瘤作用可能不仅由肿瘤微环境介导，而且还由全身外周循环淋巴细胞介导。除了疾病程度外，基线全身参数（例如外周淋巴细胞计数）可能也有助于预测 PT 治疗的疗效。 UMIN000012375，注册日期：2013年11月21日，以及UMIN000006838，注册日期：2011年12月6日。
Although peripheral blood-based parameters (PBBPs) are reported as prognostic indicators in patients with breast cancers, their utility has not been studied in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC). Tumor-infiltrating lymphocytes (TILs) might be a predictive factor in patients with HER2-positive ABC treated with pertuzumab and trastuzumab (PT) plus docetaxel. We aimed to evaluate whether PBBPs could have predictive value in HER2-positive ABC treated with pertuzumab and trastuzumab (PT) combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX). Data from 51 patients included in two single-arm, phase II trials were included in this retrospective-prospective study; the ERI + PT (N = 30) and Nab-PTX + PT (N = 21) combinations were registered under clinical trials number UMIN000012375 and UMIN000006838, respectively. We assessed PBBPs using prospectively collected data and investigated the association with progression-free survival (PFS); we evaluated absolute lymphocyte count (ALC), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). The cutoff values for ALC, NLR, and PLR were set at 1000 or 1500 cells/μL, 2, and 250, respectively. PFS was significantly improved in patients with ALC ≥1500/μL compared to those with ALC 1000–, <1500/μL or ALC < 1000/μL (P = 0.0106). High baseline ALC was significantly associated with improved PFS (≥1500/μL; hazard ratio [HR]: 0.3715; 95% confidence interval [CI]: 0.1735–0.7955; P = 0.0108). In contrast, improved PFS was not significantly associated with NLR or PLR. Improved PFS in patients with ALC ≥1500/μL was observed irrespective of visceral metastasis or chemotherapy regimen. Our results showed that baseline ALC was a predictive factor for PFS in HER2-positive ABC treated with PT irrespective of combined chemotherapy regimen. Anti-tumor effects might be mediated not only by the tumor microenvironment, but also by systemic peripheral circulating lymphocytes. Baseline systemic parameters such as peripheral lymphocyte count might be beneficial in addition to disease extent for predicting the efficacy of PT treatment. UMIN000012375, registration date: 21NOV2013, and UMIN000006838, registration date: 6DEC2011.
登录
查看更多内容
影响因子：
7.3
作者：
Efremova M;Finotello F;Rieder D;Trajanoski Z
通讯作者：
Trajanoski Z
影响因子：
82.9
作者：
Gros A;Parkhurst MR;Tran E;Pasetto A;Robbins PF;Ilyas S;Prickett TD;Gartner JJ;Crystal JS;Roberts IM;Trebska-McGowan K;Wunderlich JR;Yang JC;Rosenberg SA
通讯作者：
Rosenberg SA
影响因子：
8.8
作者：
Koh CH;Bhoo-Pathy N;Ng KL;Jabir RS;Tan GH;See MH;Jamaris S;Taib NA
通讯作者：
Taib NA
DOI：
10.1016/s1470-2045(16)30631-3
发表时间：
2017-01
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Luen SJ;Salgado R;Fox S;Savas P;Eng-Wong J;Clark E;Kiermaier A;Swain SM;Baselga J;Michiels S;Loi S
通讯作者：
Loi S
影响因子：
3.7
作者：
Asano Y;Kashiwagi S;Onoda N;Noda S;Kawajiri H;Takashima T;Ohsawa M;Kitagawa S;Hirakawa K
通讯作者：
Hirakawa K